Authors : Shiva Shankar Jha, Shiva Shankar Jha
DOI : 10.18231/j.ijor.2019.010
Volume : 5
Issue : 2
Year : 2019
Page No : 42-54
Spondyloarthropathy, a group of overlapping disorders of chronic inflammatory diseases of autoimmune nature has undergone critical changes in its management, specially with introduction of newer biologics and targeted synthetic DMARDs. Secukinumab and Tofacitinib are newer additions to proper management targeting various cytokines. Cost being an important factor in developing world, conventional synthetic DMARDs are being advocated to be used in situations where patient can not afford the treatment with biologics / small molecules i.e. JAK Inhibitors. It is heartening to know that methotrexate can achieve 20% remission in psoriatic arthritis almost equivalent to some biologics. Drug antibody is also a challenging problem in management with biologics.
Keywords: Biologic, DMARDs, Secukinumab, Tofacitinib, JAK Inhibitors, Cost.